- Home
- INCY vs GLPI Comparison
INCY vs GLPI Comparison
Compare INCY & GLPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- GLPI
- Stock Information
- Founded
- INCY 1991
- GLPI 2013
- Country
- INCY United States
- GLPI United States
- Employees
- INCY N/A
- GLPI N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- GLPI Real Estate Investment Trusts
- Sector
- INCY Health Care
- GLPI Real Estate
- Exchange
- INCY Nasdaq
- GLPI Nasdaq
- Market Cap
- INCY 13.4B
- GLPI 13.1B
- IPO Year
- INCY 1993
- GLPI N/A
- Fundamental
- Price
- INCY $58.98
- GLPI $46.89
- Analyst Decision
- INCY Hold
- GLPI Buy
- Analyst Count
- INCY 20
- GLPI 19
- Target Price
- INCY $73.06
- GLPI $53.61
- AVG Volume (30 Days)
- INCY 1.8M
- GLPI 1.7M
- Earning Date
- INCY 04-29-2025
- GLPI 04-24-2025
- Dividend Yield
- INCY N/A
- GLPI 6.48%
- EPS Growth
- INCY N/A
- GLPI 4.14
- EPS
- INCY 0.10
- GLPI 2.83
- Revenue
- INCY $4,413,226,000.00
- GLPI $1,550,817,000.00
- Revenue This Year
- INCY $12.28
- GLPI $6.89
- Revenue Next Year
- INCY $9.20
- GLPI $3.73
- P/E Ratio
- INCY $611.49
- GLPI $16.43
- Revenue Growth
- INCY 17.13
- GLPI 6.14
- 52 Week Low
- INCY $52.81
- GLPI $42.86
- 52 Week High
- INCY $83.95
- GLPI $52.60
- Technical
- Relative Strength Index (RSI)
- INCY 44.09
- GLPI 41.50
- Support Level
- INCY $57.77
- GLPI $46.21
- Resistance Level
- INCY $62.87
- GLPI $47.13
- Average True Range (ATR)
- INCY 1.78
- GLPI 0.91
- MACD
- INCY 0.20
- GLPI -0.12
- Stochastic Oscillator
- INCY 36.23
- GLPI 17.99
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About GLPI Gaming and Leisure Properties Inc.
Gaming and Leisure Properties Inc, or GLP, is a real estate investment property trust whose primary business consists of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The GLPI's portfolio consisted of interests in sixty one gaming and related facilities, the real property associated with thirty four gaming and related facilities operated by PENN, the real property associated with six gaming and related facilities operated by Caesars Entertainment Corporation.